UnicoCell Biomed Co., Ltd. (TPE:6794)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
83.10
+1.10 (1.34%)
Mar 10, 2026, 9:31 AM CST
13.06%
Market Cap 4.98B
Revenue (ttm) 30.10M
Net Income (ttm) -114.84M
Shares Out 60.68M
EPS (ttm) -1.89
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 9,000
Average Volume 86,204
Open 84.80
Previous Close 82.00
Day's Range 81.90 - 84.80
52-Week Range 60.80 - 96.00
Beta -0.37
RSI 38.33
Earnings Date Feb 25, 2026

About UnicoCell Biomed

UnicoCell Biomed Co., Ltd. engages in the research and development of stem cell drugs in Taiwan and Japan. The company develops ELIXCYTE for the treatment of knee osteoarthritis and chronic kidney disease. It also operates an allogeneic adipose stem cell bank. In addition, the company offers autologous stem cell therapy; conditioned medium; CDMO; UnicoVial, a cryogenic vial for the storage of cell products and biological samples under ultra-low temperature; and laboratory testing services, which include sterility, endotoxin, mycoplasma, and cel... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Country Taiwan
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6794
Full Company Profile

Financial Performance

In 2025, UnicoCell Biomed's revenue was 30.10 million, a decrease of -5.58% compared to the previous year's 31.88 million. Losses were -114.84 million, 23.4% more than in 2024.

Financial Statements

News

There is no news available yet.